Sanofi India Limited has informed the Exchange regarding a press release dated April 28, 2026, titled "Sanofi India Limited continues to deliver strong performance in insulin portfolio".
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanofi India's Board approved unaudited financial results for the quarter ended March 31, 2026 (Q1 FY2026). Revenue from operations stood at ₹4,723 million (down from ₹5,359 million in Q1 FY2025), with profit for the quarter at ₹1,026 million and EPS of ₹44.55 (vs ₹51.89 in the year-ago quarter). For the full year ended December 31, 2025, revenue was ₹18,374 million and net profit ₹3,267 million (after ₹273 million in one-time personnel separation costs). The press release highlighted that the domestic insulin portfolio delivered double-digit growth for the second consecutive quarter (14% QoQ and 19% YoY), but overall quarterly results were dragged down by transactions related to partnership transitions. Export sales are stabilising despite geopolitical headwinds. Additionally, the tenures of Independent Directors Mr. Aditya Narayan and Mrs. Usha Thorat ended on April 29, 2026, and Mr. Rahul Bhatnagar was appointed as the new Chairman of the Board effective April 30, 2026, with multiple board committees reconstituted accordingly.
Mixed signals for shareholders: the core insulin franchise continues to grow strongly, but a double-digit decline in overall quarterly revenue and profit reflects the expected noise from partnership transitions. The board-level changes are routine governance matters and unlikely to materially affect the stock, though investors may want clarity on the long-term margin and growth trajectory once new partnerships stabilise.